Is Pfizer’s Stock Decline a Golden Opportunity for Savvy Investors?
Pfizer's stock market performance has declined nearly 60% from its peak last year, raising concerns for growth-focused investors. Key challenges include patent expirations for leading drugs like Eliquis, Vyndaqel, and…